Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Common Herbal Dietary Supplement-Drug Interactions.

Asher GN, Corbett AH, Hawke RL.

Am Fam Physician. 2017 Jul 15;96(2):101-107. Review.

2.

Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.

Xie Y, Miranda SR, Hoskins JM, Hawke RL.

Molecules. 2017 Jan 15;22(1). pii: E142. doi: 10.3390/molecules22010142.

3.

Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers.

Asher GN, Xie Y, Moaddel R, Sanghvi M, Dossou KS, Kashuba AD, Sandler RS, Hawke RL.

J Clin Pharmacol. 2017 Feb;57(2):185-193. doi: 10.1002/jcph.806. Epub 2016 Sep 6.

4.

Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.

Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF.

Eur J Gastroenterol Hepatol. 2014 Oct;26(10):1073-82. doi: 10.1097/MEG.0000000000000152.

5.

Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.

Köck K, Xie Y, Hawke RL, Oberlies NH, Brouwer KL.

Drug Metab Dispos. 2013 May;41(5):958-65. doi: 10.1124/dmd.112.048272. Epub 2013 Feb 11.

6.

The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.

Ilic K, Hawke RL, Thirumaran RK, Schuetz EG, Hull JH, Kashuba AD, Stewart PW, Lindley CM, Chen ML.

Drug Metab Dispos. 2013 Mar;41(3):575-81. doi: 10.1124/dmd.112.048108. Epub 2012 Dec 13.

7.

Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract.

Halegoua-De Marzio D, Kraft WK, Daskalakis C, Ying X, Hawke RL, Navarro VJ.

Clin Ther. 2012 Dec;34(12):2279-2285.e1. doi: 10.1016/j.clinthera.2012.10.009. Epub 2012 Nov 13.

PMID:
23153661
8.

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR; Silymarin in NASH and C Hepatitis (SyNCH) Study Group.

JAMA. 2012 Jul 18;308(3):274-82. doi: 10.1001/jama.2012.8265.

9.

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C.

Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM; SyNCH Study Group.

Clin Trials. 2012 Feb;9(1):102-12. doi: 10.1177/1740774511427064. Epub 2011 Nov 4.

10.

Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Meyers CM, Doo E, Fried MW.

Drug Metab Dispos. 2011 Dec;39(12):2182-90. doi: 10.1124/dmd.111.040212. Epub 2011 Aug 24.

11.

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Berman J, Liu QY, Doo E, Fried MW; SyNCH Trial Group.

J Clin Pharmacol. 2010 Apr;50(4):434-49. doi: 10.1177/0091270009347475. Epub 2009 Oct 19.

12.

Warfarin dosing and the promise of pharmacogenomics.

Dumas TE, Hawke RL, Lee CR.

Curr Clin Pharmacol. 2007 Jan;2(1):11-21. Review.

PMID:
18690851
13.

Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).

Miranda SR, Lee JK, Brouwer KL, Wen Z, Smith PC, Hawke RL.

Drug Metab Dispos. 2008 Nov;36(11):2219-26. doi: 10.1124/dmd.108.021790. Epub 2008 Aug 7.

14.

The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity.

Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, Hawke RL.

Drug Metab Dispos. 2008 Sep;36(9):1909-16. doi: 10.1124/dmd.107.019604. Epub 2008 Jun 19.

PMID:
18566043
15.

The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.

Roberts PJ, Rollins KD, Kashuba AD, Paine MF, Nelsen AC, Williams EE, Moran C, Lamba JK, Schuetz EG, Hawke RL.

Drug Metab Dispos. 2008 Aug;36(8):1465-9. doi: 10.1124/dmd.107.020065. Epub 2008 May 19.

16.

The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.

Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF.

Drug Metab Dispos. 2008 Jan;36(1):146-54. Epub 2007 Oct 22.

PMID:
17954524
17.

Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.

Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC.

Drug Metab Dispos. 2008 Jan;36(1):65-72. Epub 2007 Oct 3.

PMID:
17913795
18.

Antimycotic drug discovery in the age of genomics.

Cleary JD, Walker LA, Hawke RL.

Am J Pharmacogenomics. 2005;5(6):365-86. Review.

PMID:
16336002
19.

Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity.

Lee CR, Hawke RL, Pieper JA.

Eur J Clin Pharmacol. 2005 Jun;61(4):315-6. Epub 2005 May 4. No abstract available.

PMID:
15875171
20.

Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes.

Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD.

Drug Metab Dispos. 2004 Mar;32(3):359-63.

PMID:
14977871
21.

Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.

Shord SS, Faucette SR, Gillenwater HH, Pescatore SL, Hawke RL, Socinski MA, Lindley C.

Cancer Chemother Pharmacol. 2003 Apr;51(4):328-36. Epub 2003 Mar 13.

PMID:
12721761
22.

The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes.

Lindley C, Hamilton G, McCune JS, Faucette S, Shord SS, Hawke RL, Wang H, Gilbert D, Jolley S, Yan B, LeCluyse EL.

Drug Metab Dispos. 2002 Jul;30(7):814-22.

PMID:
12065440
23.

Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.

Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM.

Drug Metab Dispos. 2001 Aug;29(8):1123-9.

PMID:
11454731
24.

In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone.

McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C.

Clin Pharmacol Ther. 2000 Oct;68(4):356-66.

PMID:
11061575
25.

Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM.

Drug Metab Dispos. 2000 Oct;28(10):1222-30.

PMID:
10997944
26.

Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity.

Hawke RL, Chapman JM, Winegar DA, Salisbury JA, Welch RM, Brown A, Franzmann KW, Sigel C.

J Lipid Res. 1997 Jun;38(6):1189-203.

27.

Cubital tunnel syndrome in a collegiate wrestler: a case report.

Bruce SL, Wasielewski N, Hawke RL.

J Athl Train. 1997 Apr;32(2):151-4.

28.

Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells.

Winegar DA, Salisbury JA, Sundseth SS, Hawke RL.

J Lipid Res. 1996 Jan;37(1):179-91.

30.

Regulation of microsomal testosterone 15 alpha-hydroxylase activity in inbred mouse liver and kidney.

Neims AH, Hawke RL, Raynor L, Singh G.

Biochem Soc Trans. 1984 Feb;12(1):45-8. No abstract available.

PMID:
6705987
31.

Maturation of various testosterone hydroxylase activities in hepatic microsomes from AKR/J mice.

Hawke RL, Neims AH.

Prog Clin Biol Res. 1983;135:25-35. No abstract available.

PMID:
6665006

Supplemental Content

Loading ...
Support Center